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Abstract
Background: Luteolin is a 3’,4’,5,7-tetrahydroxyflavone found in various fruits and vegetables. We have shown
previously that luteolin reduces HT-29 cell growth by inducing apoptosis and cell cycle arrest. The objective of this
study was to examine whether luteolin downregulates the insulin-like growth factor-I receptor (IGF-IR) signaling
pathway in HT-29 cells.
Methods: In order to assess the effects of luteolin and/or IGF-I on the IGF-IR signaling pathway, cells were cultured
with or without 60 μmol/L luteolin and/or 10 nmol/L IGF-I. Cell proliferation, DNA synthesis, and IGF-IR mRNA
levels were evaluated by a cell viability assay, [
3H]thymidine incorporation assays, and real-time polymerase chain
reaction, respectively. Western blot analyses, immunoprecipitation, and in vitro kinase assays were conducted to
evaluate the secretion of IGF-II, the protein expression and activation of IGF-IR, and the association of the p85
subunit of phophatidylinositol-3 kinase (PI3K) with IGF-IR, the phosphorylation of Akt and extracellular signal-
regulated kinase (ERK)1/2, and cell division cycle 25c (CDC25c), and PI3K activity.
Results: Luteolin (0 - 60 μmol/L) dose-dependently reduced the IGF-II secretion of HT-29 cells. IGF-I stimulated HT-
29 cell growth but did not abrogate luteolin-induced growth inhibition. Luteolin reduced the levels of the IGF-IR
precursor protein and IGF-IR transcripts. Luteolin reduced the IGF-I-induced tyrosine phosphorylation of IGF-IR and
the association of p85 with IGF-IR. Additionally, luteolin inhibited the activity of PI3K activity as well as the
phosphorylation of Akt, ERK1/2, and CDC25c in the presence and absence of IGF-I stimulation.
Conclusions: The present results demonstrate that luteolin downregulates the activation of the PI3K/Akt and ERK1/
2 pathways via a reduction in IGF-IR signaling in HT-29 cells; this may be one of the mechanisms responsible for
the observed luteolin-induced apoptosis and cell cycle arrest.
Background
Colon cancer is the second most frequent cause of can-
cer-related death in the Western world [1]. Dietary pat-
terns and lifestyle are the principal determining factors
for colorectal cancer risk. The results of epidemiological
studies have shown that the consumption of fruits and
vegetables can reduce or prevent the risk of colon can-
cer [2]. Flavonoids are polyphenols, which are
abundantly present in fruits and vegetables, and have
been shown to have a variety of biological effects,
including cancer prevention.
Insulin-like growth factors (IGFs) are polypeptides that
stimulate the growth of a variety of mammalian cells [3].
These effects are mediated through the insulin-like
growth factor I receptor (IGF-IR), and IGF-I and IGF-II
are well-known ligands of IGF-IR. The binding of these
ligands to IGF-IR results in the autophosphorylation of
the receptor at the intracellular domain of b-subunits,
resulting in the activation of the intrinsic tyrosine kinase
of the IGF-IR. Subsequently, several adaptor molecules
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distinct signaling pathways are activated by IGF-IR. The
recruitment and activation of growth factor receptor-
bound protein-2/son of sevenless or Shc can lead to the
recruitment and activation of the Ras/Raf/mitogen acti-
vated protein kinase (MAPK) cascade, ultimately result-
ing in the activation of extracellular signal-regulated
kinase (ERK)1/2. Alternatively, insulin receptor sub-
strate-1 can be recruited and phosphorylated on multi-
ple tyrosine residues that function as docking sites for
the p85 subunit of phosphatidylinositol 3-kinase (PI3K)
and activate the PI3K/Akt signaling pathway (reviewed
in [4,5]). The activation of these pathways induces cell
cycle progression and prevents apoptosis [6,7]. IGFs are
also strong mitogens and survival factors for a variety of
cancer cells, including prostate and colon cancer cells
(Reviewed in [8]), and IGF-I and IGF-II mRNA levels
were reported to be highly elevated in colon cancer [9].
We have previously reported that, in human colon can-
cer cells, including HT-29 cells and Caco-2 cells, IGF-II
is synthesized and secreted, and an IGF-II autocrine
loop stimulates the growth of these cancer cells [10,11].
Luteolin, 3’,4’,5,7-tetrahydroxyflavone, is found in a
variety of vegetables, fruits, and medicinal herbs. Luteo-
lin has been shown to function as an anti-oxidant, anti-
inflammatory, and anti-cancer agent [12-15]. Addition-
ally, luteolin induces cell cycle arrest and apoptosis in
the liver and lung cancer and leukemia cell lines
[16-20]. Our previous results indicated that luteolin
inhibited HT-29 cell proliferation by inducing cell cycle
arrest and apoptosis [21]. Therefore, in this study, we
attempted to determine whether luteolin downregulates
IGF-IR signaling in HT-29 cells.
Methods
Cell culture
Human colon cancer cells (HT-29 and Caco-2 cells) and
rat intestinal epithelial cell line-6 (IEC-6 cells) were pur-
chased from the American Type Culture Collection (Man-
assas, VA) and maintained in DMEM/F12 containing 100
mL/L of fetal bovine serum (FBS), with 100,000 U/L of
penicillin and 100 mg/L of streptomycin. In order to
determine the effects of luteolin and/or IGF-I on cell
growth, we plated the cells with DMEM/F12 containing
10% FBS. Prior to luteolin treatment, the cell monolayers
were subjected to 24 h of serum starvation with DMEM/
F12 supplemented with 5 mg/L transferrin, 1 g/L BSA,
and 5 μg/L selenium (serum-free medium). The cells were
then incubated in serum-free medium with or without 60
μmol/L of luteolin (Sigma, St. Louis, MO, USA) and/or 10
nmol/L IGF-I (R & D System, Minneapolis, MN, USA) for
2 4 ,4 8o r7 2h .V i a b l ec e l ln u m b e r sw e r ee s t i m a t e dv i a
MTT assays. Luteolin was dissolved in DMSO and all cells
were treated with DMSO at a final concentration of 0.1%.
[
3H]Thymidine incorporation assay
To determine DNA synthesis, the cells were plated at a
density of 6,000 cells per well in 96-well plates and
serum-starved as described above. After serum starva-
tion, the cells were incubated for 2 h in serum-free
medium containing 0 or 60 μmol/L of luteolin with or
without IGF-I. 0.5 μCi [
3H]thymidine was then added,
and the incubation was continued for another 1 h. The
incorporation of [
3H]thymidine into DNA was estimated
as previously described [11].
IGF-II determination
For the determination of IGF-II, HT-29 cells were pla-
ted in 100 mm dishes at a concentration of 2 × 10
6
cells/dish and after 24 h, the monolayers were serum-
starved and treated with various concentrations of luteo-
lin (0 - 60 μmol/L) for 24 h. Conditioned media were
collected and concentrated 20-fold, and immunoblot
analysis was conducted using anti-IGF-II clone S1F2
(Upstate Biotechnology, Inc., Lake Placid, NY, USA) as
previously described [22].
Immunoprecipitation and immunoblot analyses
Cells were incubated for 2 h with 0 or 60 μmol/L of
luteolin, and 10 nmol/L of IGF-I was added. At 0, 1, or
30 min after the addition of IGF-I, the cell lysates were
prepared and immunoprecipitated with indicated antibo-
dies. Immunoblot analyses were conducted as described
previously [23]. Signals were detected via the enhanced
chemiluminescence method using SuperSignal West
Dura Extended Duration Substrate (Pierce, Rockford, IL,
USA). The relative abundance of each protein band was
analyzed via densitometric scanning of the exposed
films. Immunoblots were probed with an antibody for
b-actin as a protein loading control. The following anti-
bodies were purchased from the indicated suppliers:
anti-IGF-IRb (C-20) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA); anti-phospho-tyrosine-RC20
antibody (PY20) linked to horseradish peroxidase
(Transduction Laboratories, Palo Alto, CA, USA); anti-
PI3K p85 antibody (Upstate Biotechnology, Inc.); anti-
phospho-IGF-IR (P-IGF-IR, Abcam, Cambridge, MA,
USA); and anti-ERK-1/2, anti-P-ERK-1/2 (Thr202/
Tyr203), anti-cell division cycle 25c (CDC25c), anti-P-
CDC25c, anti-Akt, and anti-P-Akt Ser473 (Cell Signaling
Technology, Inc., Beverly, MA, USA).
Real-time-polymerase chain reaction (RT-PCR)
Total RNA was isolated using RNeasy Plus Mini Kit
(Qiagen, Valencia, CA, USA) and cDNA was synthesized
using 3 μg of total RNA with SuperScript II reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). Real
time-PCR was conducted as described previously [24].
Sequences used for primer sets were as follows: IGF-IR;
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ward-TGA TGA CCA GTG TTG GCT GG, b-actin;
forward-GTT TGA GAC CTT CAA CAC CCC, back-
ward-GTG GCC ATC TCC TGC TCG AAG TC. The
levels of mRNA were normalized to b-actin and the
control (0 μmol/L luteolin) levels were set to 100%.
PI3K assay
PI3K activity was estimated as described previously [25].
Cell lysates (1 mg protein) were immunoprecipitated
with a polyclonal antibody against IGF-IRb followed by
incubation with protein A-Sepharose beads. After wash-
ing, the beads were resuspended in 20 μL of kinase buffer
containing 4 μg of phosphatidylinositol (Sigma, St. Louis,
MO, USA), 10 μmol/L of ATP, 5 mmol/L of MnCl2,a n d
10 μCi of [g-
32P]ATP and incubated for 20 min at 30°C.
In order to determine whether luteolin directly inhibits
the kinase activity of PI3K, active PI3Ka (100 ng, Milli-
pore, Billerica, MA, USA) was incubated for 10 min in
the absence or presence of 20 μmol/L of luteolin at 30°C
in 20 μL of kinase buffer. Phosphatidylinositol (25 μg)
was added and the incubation was continued for another
5 min at room temperature. 10 μCi of [g-
32P]ATP was
then added and reactions were incubated for 10 min at
30°C. The resultant
32P-labeled phosphatidylinositol 3-
phosphate (PIP) lipids were separated from reaction pro-
ducts by thin layer chromatography (TLC) and visualized
by autoradiography. The radioactive PIP signals were
quantitated via densitometry using the Bio-profile Bio-1D
application (Vilber-Lourmat, France) [23].
Statistical analyses
Data were expressed as means ± SEM values and ana-
lyzed via analysis of variance. Differences between treat-
ment groups were analyzed by Duncan’sm u l t i p l er a n g e
test or Student’s t-test. The means were considered sig-
nificantly different at P < 0.05. All statistical analyses
were conducted using the SAS system for Windows,
version 8.12 (SAS, Inc., Cary, NC, USA).
Results
Luteolin reduces IGF-II secretion in HT-29 cells
In the previous study, we observed that luteolin inhib-
ited HT-29 human colon cancer cell proliferation by
inducing cell cycle arrest and apoptosis [21]. However,
the treatment of IEC-6 rat intestinal epithelial cells at
the same concentrations (20 - 60 μmol/L) of luteolin for
24 h did not alter the viability of these cells (data not
shown). In order to assess the effect of luteolin on IGF-
II secretion of HT-29 cells, cells were treated with 20 -
60 μmol/L of luteolin for 24 h and conditioned media
were assayed via immunoblot analysis. Luteolin reduced
the secretion of pro- and mature-IGF-II in a dose-
dependent manner (Figure 1).
Luteolin abrogates the growth stimulatory effects of
exogenous IGF-I on HT-29 cells
In order to determine whether luteolin inhibits the
growth-stimulatory effects of exogenous IGF-I, cells
were treated with 0 or 60 μmol/L of luteolin in the
absence or presence of 10 nmol/L IGF-I for 24, 48, or
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Figure 1 Luteolin reduces IGF-II secretion dose-dependently in
HT-29 human colon cancer cells.( A) HT-29 cells were plated at a
density of 2 × 10
6 cells/100 mm dish in DMEM/F12 supplemented
with 10% FBS. After 24 h, cells were serum-starved with serum-free
DMEM/F12 supplemented with 5 mg/L of transferrin and 5 μg/L of
selenium for 24 h. Cells were treated with various concentrations (0
-6 0μmol/L) of luteolin. 24 h after luteolin treatment, conditioned
media were collected and concentrated for immunoblot analysis
with an anti-IGF-II antibody. The volumes of media loaded onto the
gels were adjusted for equivalent cell numbers. Photographs of the
chemiluminescent detection of the blot, which were representative
of three independent experiments, are shown. (B) The relative
abundance of each band was quantified via densitometric scanning
of the exposed films, and the control levels were set at 100%. Each
bar represents the mean ± SEM (n = 3). Means without a common
letter differ, P < 0.05.
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the numbers of viable cells. The treatment of cells with
IGF-I did not alleviate the growth-inhibitory effects of
luteolin (Figure 2A). To explore the effect of luteolin on
DNA synthesis in HT-29 cells, an [
3H]thymidine incor-
poration assay was conducted. DNA synthesis was
induced by IGF-I treatment, and luteolin significantly
inhibited the stimulatory effect of IGF-I (Figure 2B).
Luteolin reduces the levels of the IGF-IR precursor protein
and IGF-IR transcripts in HT-29 cells
Because luteolin reduced IGF-II secretion but exogenous
IGF-I did not abrogate the growth-inhibitory effect of
luteolin, we attempted to determine whether luteolin
inhibits the IGF-I signaling pathway. Western blot ana-
lysis revealed that the levels of the IGF-IR precursor
protein were reduced 2 h after the addition of luteolin,
whereas the levels of the IGF-IR b-subunit were unal-
tered (Figure 3A). Additionally, IGF-IR transcript levels
were reduced dose-dependently in cells treated with
luteolin for 2 h (Figure 3B). Furthermore, the levels of
IGF-IR mRNA were reduced further at 24 h of luteolin
treatment as compared to those at 2 h (Figure 3C).
Luteolin inhibits IGF-I-induced activation of IGF-IR, Akt,
and ERK1/2 in HT-29 cells
In order to determine whether luteolin down-regulates
IGF-I-induced tyrosine phosphorylation of the IGF-IR,
c e l l sw e r et r e a t e df o r2hw i t h0o r6 0μmol/L of luteo-
lin, and IGF-IR was stimulated with 10 nmol/L IGF-I
for 0, 1, or 30 minutes. Total cell lysates were prepared
and immunoprecipitated using an IGF-IRb antibody.
T h ei m m u n ec o m p l e x e sw e re used for Western blot
analysis with an anti-P-tyrosine antibody (PY20). IGF-I
induced tyrosine phosphorylation of IGF-IR at 1 min;
tyrosine phosphorylation levels were slightly reduced at
30 min. Luteolin significantly inhibited the phosphoryla-
tion of IGF-IRb at 1 min after IGF-I treatment. At 30
min, the phosphorylation status of IGF-IR did not differ
between the control and luteolin-treated cells.
To evaluate the association of the p85 subunit of PI3K
with IGF-IR, we conducted immunoprecipitation of cell
lysates with an IGF-IRb antibody and subsequent immu-
noblotting with a p85 antibody. IGF-I stimulated the
association of the p85 regulatory subunit of PI3K with
IGF-IR within 1 min, which was significantly inhibited
by luteolin treatment (Figure 4A). The association of
p85 with IGF-IR was reduced at 30 min, and no differ-
ence was observed in the association of these two mole-
cules between the control and luteolin-treated cells at
this time period. Western blot analysis of total cell
lysates revealed that IGF-I markedly increased P-IGF-IR
levels and luteolin reduced those in both HT-29 and
Caco-2 cells (Figure 4B). For the determination of PI3K
activity, the immune complex was incubated with [
32P]
ATP and phosphatidylinositol. Luteolin reduced both
basal and IGF-I-induced PI3K activity in HT-29 cells at
1 min of IGF-I treatment. However, this difference dis-
appeared at 30 min after IGF-I treatment (Figure 4C).
In order to determine whether the luteolin-induced
inhibition of PI3K is the result of direct interaction with
this kinase, active PI3K was incubated with 20 μmol/L
of luteolin in the kinase reaction. Luteolin inhibited
PI3K activity in a cell-free system (Figure 4D). The acti-
vation of PI3K leads to the activation of Akt [7]. Akt
phosphorylation was induced by IGF-I treatment at 1
min without any changes in total Akt expression;
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Figure 2 Luteolin abrogates the growth-stimulatory effects of
exogenous IGF-I in HT-29 cells.( A) HT-29 cells were plated in 24-
well plates at a density of 5 × 10
4 cells/well. One day later, the cells
were serum-starved for 24 h with serum-free DMEM/F12
supplemented with 5 mg/L transferrin, 0.1 g/L BSA, and 5 μg/L
selenium for 24 h. After serum-starvation, the cells were incubated
in serum-free medium containing 0 or 60 μmol/L of luteolin with or
without 10 nmol/L of IGF-I for 24, 48, and 72 h. Viable cell numbers
were estimated via an MTT assay. (B) Cells were plated in 96-well
plates at a density of 6 × 10
3 cells/well. Cells were serum-starved
and then treated with 0 or 60 μmol/L of luteolin with or without 10
nmol/L of IGF-I for 2 h. [
3H]Thymidine was then added, and the
incubation was continued for an additional 1 h in order to measure
its incorporation into DNA. Each bar represents the mean ± SEM (n
= 6). Means without a common letter differ, P < 0.05.
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(Figure 5).
IGF-I stimulated ERK1/2 activation in HT-29 cells was
detected at 30 min of IGF-I treatment, and luteolin
inhibited the phosphorylation of ERK1/2 in the absence
or presence of IGF-I treatment (Figure 6). Because
ERK1/2 activation was reported to lead to the activation
of the protein phosphatase CDC25c during the G2/M
transition of cell cycle progression [26], we subsequently
attempted to determine whether luteolin treatment
results in a reduction in the phosphorylation of
CDC25c. The levels of P-CDC25c were increased at 30
min after IGF-I addition and significantly reduced in
cells treated with luteolin, regardless of whether or not
the HT-29 cells were treated with IGF-I (Figure 6C).
Discussion
The IGF system (IGF-I, IGF-II, IGF-binding protein,
and IGF-IR) performs an important role in the growth
of various cancer cells, including colon cancer cells
[8,27]. We have reported previously that luteolin inhib-
ited the proliferation of HT-29 human colon cancer
cells by inducing cell cycle arrest and apoptosis [21].
The results of a previous study revealed that luteolin
reduced the expression of cyclin D1 and cyclin B1 and
inhibited the activities of CDKs, thereby suppressing
HT-29 cell cycle progression. Additionally, luteolin
induced the activation of caspases and reduced the
levels of proteins involved in the suppression of apopto-
sis, including Bcl-xL and Mdm-2 [21]. Thus, in the pre-
sent study, we explored the upstream signals that are
important for the regulation of cell cycle progression
and apoptosis in HT-29 cells. Our previous data
demonstrated that HT-29 cells synthesized and secreted
IGF-II and expressed IGF-IR, and that IGF-II stimulated
HT-29 cell growth via an autocrine mechanism [10,28].
Kim et al. also reported that the reduction of IGF-II
secretion in Caco-2 colon cancer cells inhibited cell
growth [11]. Using PC-3 and DU145 human prostate
cancer cells, Fang et al. [29] have demonstrated that
luteolin inhibits the IGF-I-induced activation of IGF-IR
and AKT as well as the downstream targets of AKT,
p70S6K1, GSK-3b, and FKHR/FKHRL1. In the present
study, we demonstrate that, in HT-29 human colon car-
cinoma cells, luteolin 1) reduces IGF-II secretion; 2)
inhibits the growth-stimulatory effects of IGF-I; 3)
reduces the levels of IGF-IR transcripts and the IGF-IR
precursor protein; 4) reduces the IGF-I-induced tyrosine
phosphorylation of IGF-IRb and the association of p85
with IGF-IRb; 5) inhibits IGF-I-induced PI3K activity 6)
inhibits IGF-I-induced Akt activation; and 7) inhibits
the IGF-I-induced phosphorylation of ERK1/2 and
CDC25c. These results indicate that the reduction in
IGF-II secretion and changes in IGF-IR signaling by
luteolin may be important factors underlying the
growth-inhibitory effects of HT-29 cells. Additionally,
we have demonstrated that luteolin directly inhibits the
activity of PI3K in a cell-free system.
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Figure 3 Luteolin reduces the levels of the IGF-IR protein and
mRNA in HT-29 cells.( A) HT-29 cells were plated and treated with
luteolin as described in Figure 1 for 2 h. Total cell lysates were
prepared and immunoblot analyses were conducted. Photographs
of the chemiluminescent detection of the blots, which were
representative of three independent experiments, were shown. The
relative abundance of IGF-IR to their own b-actin was quantified via
densitometric scanning of the exposed films, and the control levels
were set at 100%. (B)HT-29 cells were plated and treated with
luteolin as described in Figure 1 for 2 h. (C)HT-29 cells were treated
with 0 or 60 μmol/L of luteolin for 2, 8, and 24 h. (B, C) Total RNA
was isolated and real-time PCR was conducted. Each bar represents
mean ± SEM (n = 3). (A, B) Means without a common letter differ,
P < 0.05. (C) *Different from 0 μmol/L of luteolin at each treatment
time, P < 0.05.
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Figure 4 Effects of luteolin on IGF-I-induced tyrosine phosphorylation of IGF-IR, the association of p85 with IGF-IR, and PI3K activity in
human colon cancer cells. Cells were plated and cultured as described in Figure 1. (A) HT-29 cells were treated for 2 h with 0 or 60 μmol/L of
luteolin and lysed with or without stimulation of 10 nmol/L IGF-I for 0, 1, or 30 minutes. Total cell lysates were incubated with anti-IGF-IRb
antibody and the immune complexes were precipitated with protein A-Sepharose. The immunoprecipitated proteins were analyzed via Western
blotting with antibodies raised against phosphotyrosine (PY20), IGF-IRb, or p85. (B) HT-29 and Caco-2 cells were plated and treated as described
above. Total cell lysates were analyzed via Western blotting with an antibody raised against P-IGF-IR. Photographs of the chemiluminescent
detection of the blots, which were representative of three independent experiments, were shown. (C) The immune complexes obtained from
HT-29 cells were incubated with phosphatidylinositol and [g-
32P]ATP. (D) Active PI3K and luteolin were incubated with phosphatidylinositol and
[g-
32P]ATP as described in the Materials and Methods section. Phosphatidylinositol 3-phosphate (PIP) generated by immunoprecipitated PI3K (C)
or active PI3Ka (D) was separated via thin-layer chromatography (TLC). An autoradiograph of the TLC plate, which was representative of three
independent experiments, is shown. (A, B, C) The relative abundance of each blot was quantified via densitometric scanning of the exposed
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*Different from 0 μmol/L of luteolin at a stimulation time, P < 0.05.
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Page 6 of 10When HT-29 cells were treated with exogenous IGF-I,
IGF-I did not abrogate the growth-inhibitory effects of
luteolin (Figure 2), although luteolin reduced IGF-II
secretion (Figure 1). These results indicated that luteolin
inhibits IGF-IR signaling in HT-29 cells. IGF-IR consists
of two extracellular a-subunits and two transmembrane
b-subunits, and IGF-I and IGF-II bind to the a-subunits
of IGF-IR, thus resulting in the activation of the intrin-
sic tyrosine kinase in the intracellular domain of the b-
subunits [28]. In this study, luteolin reduced the levels
of the IGF-IR precursor but did not reduce the levels of
IGF-IR b-subunits; this suggests that the levels of IGF-
IR a-subunits may have been reduced by luteolin treat-
ment. The finding that IGF-IR mRNA levels were con-
tinuously decreased during 24 h of luteolin treatment
(Figure 3C) indicates that the expression of IGF-IR pro-
tein is regulated by luteolin, at least in part, at an RNA
level. The effects of luteolin on IGF-IR mRNA and pro-
tein stability will require further study in the future.
Fang et al. demonstrated that prostate cancer cells in
which the IGF-IR gene is knocked down grew at a
slower rate relative to that in control cells, and the inhi-
bition of cell growth by luteolin treatment was similar
to that observed in IGF-IR-depleted cells [29]. In this
study, we demonstrate that luteolin inhibits IGF-II
secretion, and that IGF-I-stimulated HT-29 cell prolif-
eration was inhibited by luteolin (Figure 2). These
results suggest that the inhibition of the IGF/IGF-IR sig-
naling pathway by luteolin might be one of the mechan-
isms for the suppression of proliferation and apoptosis
in HT-29 cells. In 1994, Lahm et al. demonstrated that
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Figure 5 Luteolin inhibits IGF-I-induced Akt activation in HT-29
cells. Cells were plated and treated as described in Figure 4. Total
lysates were prepared and immunoblot analyses were conducted
with antibodies raised against p-Akt, Akt, or b-actin. (A) Photographs
of the chemiluminescent detection of the blots, which were
representative of three independent experiments, were shown. (B)
The levels of P-Akt to its own Akt control band on immunoblots
were quantified via densitometric scanning of the exposed films,
and the control levels (0 μmol/L luteolin, without IGF-I stimulation)
were set at 1. Each bar represents the mean ± SEM (n = 3).
*Different from 0 μmol/L of luteolin at a stimulation time, P < 0.05.
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Figure 6 Luteolin inhibits IGF-I-induced ERK1/2 and CDC25c
activation in HT-29 cells. Cells were plated and treated as
described in Figure 4. Total lysates were prepared and immunoblot
analyses were conducted with antibodies raised against P-ERK1/2,
ERK1/2, P-CDC25c, CDC25c, or b-actin. (A) Photographs of the
chemiluminescent detection of the blots, which were representative
of three independent experiments, were shown. (B, C) The levels of
P-ERK1/2 to its own ERK1/2 control band (B) and those of P-CDC25c
to its own CDC25c control band (C) on immunoblots were
quantified via densitometric scanning of the exposed films, and the
control levels (0 μmol/L luteolin, without IGF-I stimulation) were set
at 1. Each bar represents the mean ± SEM (n = 3). *Different from 0
μmol/L of luteolin at a stimulation time, P < 0.05.
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Page 7 of 10Alpha IR3, a neutralizing monoclonal antibody directed
against human IGF-IR, inhibited proliferation in HT-29
cells [30]. It has also been demonstrated that the block-
ade of IGF-IR with IGF-IR monoclonal antibodies inhib-
ited proliferation, arresting the cell cycle and inducing
the apoptosis of HT-29 cells [31]. Additionally, an anti-
human/mouse IGF-II-neutralizing antibody effectively
inhibited the hepatic metastasis of HT-29 cells [32]. In
vitro experiments have also demonstrated that IGF-II-
neutralizing antibody treatment completely blocked
IGF-IR phosphorylation in serum-starved HT-29 cells
[33]. These results indicate that IGF-II is an autocrine
growth factor of HT-29 cells and that the inhibition of
IGF-II secretion and/or IGF-IR signaling inhibits HT-29
cell proliferation.
In our HT-29 cells, it is possible that the luteolin-
induced downregulation of the IGF-IR a-subunit results
in reduced phosphorylation of the b-subunit. It is also
possible that luteolin directly interferes with the binding
of IGF-I to IGF-IR, which would consequently inhibit the
phosphorylation of the b-subunit. This reduced IGF-I-
induced tyrosine phosphorylation of IGF-IRb by luteolin
led to the reduced association of p85 with IGF-IRb and
the subsequent activation of PI3K/Akt and ERK1/2 (Fig-
ures 4, 5 and 6). Additionally, luteolin inhibited PI3K
activity in a cell-free system (Figure 4D), thereby indicat-
ing that luteolin can also modulate the activity of this
enzyme via direct interaction with this kinase. As the
activation of Akt and ERK1/2 induces cell proliferation
and inhibits apoptosis in various cancers [34,35], the
PI3K/Akt and ERK1/2 pathways may be important tar-
gets in cancer therapies involving natural bioactive com-
pounds [6,23,28,29,36-38]. Akt regulates the expression
and activity of proteins involved in the regulation of
apoptosis and cell cycle progression, including Bad, p21,
cyclin D1, and Mdm-2 (Reviewed in [37]). Previously, we
have demonstrated that luteolin downregulates the
expression of Mdm-2 and cyclin D1 [21]. Fang et al. also
reported that luteolin treatment induced a reduction in
the levels of P-IGF-IR, P-Akt, and cyclin D1 in PC3 pros-
tate cancer cells [29]. The results of previous studies and
of the present study indicate that the inhibition of Akt
activation by luteolin may result in the downregulation of
Mdm-2 and cyclin D1, which may contribute to the
induction of apoptosis and cell cycle arrest in colon and
prostate cancer cells. Collectively, these results indicate
that the downregulation of IGF-IR/PI3K/Akt by luteolin
is one of the principal signaling pathways for the induc-
tion of cell cycle arrest and apoptosis in HT-29 cells.
ERK-MAP kinases also regulate cell cycle- and apop-
tosis-related proteins. ERK1/2 activation leads to the
phosphorylation of the protein phosphatase CDC25c
during the G2/M transition of cell cycle progression
[26]. Phosphorylated CDC25c dephosphorylates CDC2,
which results in the activation of the CDC2/cyclin B1
complex. Luteolin has been reported to reduce the levels
of the CDC25c, CDC2, and cyclin B1 proteins and
induces G2/M phase arrest in human gastric cancer cell
lines [39]. In our previous study, luteolin reduced cyclin
B1 levels, markedly inhibited CDC2 activity, and pro-
moted G2/M phase arrest in HT-29 cells [21]. In the
present study, we determined that luteolin reduced the
levels of P-CDC25c in HT-29 cells (Figure 6C).
Together, these results indicate that the attenuated
ERK1/2 activation contributed to the reduction of P-
CDC25c levels in luteolin-treated cells. The reduction in
CDC25c activation may have contributed to the induc-
tion of G2/M arrest in HT-29 cells.
Conclusions
We demonstrated that luteolin reduced the secretion of
pro- and mature-IGF-II and reduced the levels of the
IGF-IR precursor protein in HT-29 cells, and subse-
quently reduced the activation of the Akt and ERK1/2
pathways. The inhibition of the IGF-IR signaling path-
way may be one of the mechanisms by which luteolin
inhibits Akt and ERK1/2 signaling in HT-29 cells,
thereby inhibiting cell growth and inducing apoptosis
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Figure 7 A tentative scheme for luteolin regulation of the IGF-
IR signaling pathway in HT-29 human colon cancer cells.
Luteolin reduces the secretion of IGF-II and levels of IGF-IR mRNA
and protein, which leads to a reduction in IGF-IR phosphorylation
and a subsequent inhibition of PI3K/Akt and ERK1/2/CDC25c
activation. Additionally, luteolin directly inhibits PI3K activity. These
changes in IGF-I signaling contribute to luteolin-induced apoptosis
and cell cycle arrest in HT-29 cells. *From our previously published
results [21].
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Page 8 of 10mechanisms of luteolin actions for future animal studies
with colon cancer models. Such studies will determine
whether luteolin can be developed into a chemopreven-
tive agent for use against colon cancer.
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